Affitech, Pharmexa to reverse-merge

Affitech (Oslo, Norway) will reverse-merge with Pharmexa (CSE:PHARMX). Affitech shareholders will own 70% of the combined company, and Pharmexa shareholders the remaining 30%. The newco will combine Affitech's antibody discovery capabilities and preclinical pipeline with Pharmexa's drug development capabilities, processes and infrastructure, and will focus on human mAbs to treat cancer and other diseases. The combined company will retain Affitech's name and Pharmexa's headquarters in Horsholm, Denmark. ...